A Phase 1/2 interventional study of Stem cell and Plasmalyte A in Myocardial Infarction, sponsored by Stempeutics Research Pvt Ltd. Completed at 4 sites in India. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-03-05.
Sponsored by Stempeutics Research Pvt Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Myocardial Infarction with a site in India — 1 open to participants now, 5 under way, 5 of them phase 3. Myocardial Infarction · India.
Among the 35 studies in Myocardial Infarction with a site in India, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1/2, and was the 15th registered.
2,272 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →1 of the 35 studies in Myocardial Infarction with a site in India is open now. Recruiting first, the newest first:
Viatris Innovation GmbH · Sites in India, United States, Australia and 44 more countries
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 21 · Phase 4 4
First in 2002; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 3,712 across the 31 interventional studies, 8,492 across the 4 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 35 have an industry lead sponsor. The 10 most frequent:
Stempeutics Research Pvt Ltd is the lead sponsor of 8 studies on the registry; none are open to participants now.
Stempeutics Research Pvt Ltd has 1 study filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
2 of the studies in Myocardial Infarction with a site in India that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 35 studies in Myocardial Infarction with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Stem cell
Drug: Plasmalyte A
IV infusion of stem cells
IV infusion
AE and ECG parameters
Time frame: 6 months
Regional myocardial perfusion and infarct size
Time frame: 6 months
The record gives a start of Apr 2009, a primary completion of May 2010 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stem Cell
Stempeutics Research Pvt Ltd